Molecular classification and biomarkers of outcome with immunotherapy in extensive-stage small-cell lung cancer: analyses of the CASPIAN phase 3 study.

Evaluation of OS with D + T + EP versus D + EP according to IHC analysis of MHC I expression showed a trend towards increasing OS benefit with D + T + EP with higher MHC I %TC (Fig. 6 C), with HRs for the comparisons of OS between D + T + EP and D + EP ranging from 1.81 (95% CI, 0.98–3.35), favoring D + EP, in patients with MHC I TC of 0–25% to 0.68 (95% CI, 0.28–1.62), favoring D + T + EP, in those with MHC I TC of 75–100%.

also in 53,322 other papers